Rheos Medicines Information

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop a novel class of medicines with potential to transform the lives of patients with immune mediated diseases. We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function and fate coupled to a biomarker discovery effort with potential to bring precision to the treatment of immune-mediated diseases. Launched in 2018 by Third Rock Ventures with a $60 million Series A financing, Rheos is built on groundbreaking science from pioneers in the field, our passionate team of more than 35 employees is advancing a novel pipeline of immunometabolism drugs, and in December 2019, we entered into a worldwide collaboration with Roche to identify and develop new therapeutics for autoimmune and inflammatory disease. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced leadership team that integrates immunology, metabolism, computational biology, and drug discovery to unlock a new frontier in precision medicine for immune mediated disease.